MGMT and glioblastoma: Although GBM patients with methylated MGMT and deficient mismatch repair often have a better prognosis with CCNU, the six-months progression-free survival (19%) and median overall survival (7.1 months) remains low, particularly in recurrent GBM patients as demonstrated in phase III clinical trial [49].